Adaptimmune Therapeutics annual revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Adaptimmune Therapeutics Revenue Growth & History (ADAPY)
Adaptimmune Therapeutics reported $178.0M in revenue for fiscal 2024, an increase of 195.34% from the previous fiscal year.
View full Adaptimmune Therapeutics company overviewAdaptimmune Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $178.0M | $117.8M | +195.34% |
| 2023 | 2023-12-31 | $60.3M | $33.1M | +122.05% |
| 2022 | 2022-12-31 | $27.1M | $21.0M | +341.50% |
| 2021 | 2021-12-31 | $6.1M | $2.2M | +55.36% |
| 2020 | 2020-12-31 | $4.0M | $2.8M | +252.76% |
| 2019 | 2019-12-31 | $1.1M | −$58.4M | −98.11% |
| 2018 | 2018-12-31 | $59.5M | $21.7M | +57.28% |
| 2017 | 2017-12-31 | $37.8M | $23.6M | +166.47% |
| 2016 | 2016-12-31 | $14.2M | — | — |
| 2015 | 2015-06-30 | $9.9M | $9.0M | +1096.48% |
| 2014 | 2014-06-30 | $825,000 | — | — |
Adaptimmune Therapeutics quarterly revenue
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | $13.7M | −$114.6M | −89.33% |
| Q1 2025 | 2025-03-31 | $7.3M | $1.6M | +28.30% |
| Q4 2024 | 2024-12-31 | $3.2M | $3.0M | +1294.81% |
| Q3 2024 | 2024-09-30 | $40.9M | $33.6M | +458.83% |
| Q2 2024 | 2024-06-30 | $128.2M | $123.1M | +2399.63% |
| Q1 2024 | 2024-03-31 | $5.7M | −$41.9M | −88.07% |
| Q4 2023 | 2023-12-31 | $231,000 | −$10.8M | −97.91% |
| Q3 2023 | 2023-09-30 | $7.3M | $312,000 | +4.45% |
| Q2 2023 | 2023-06-30 | $5.1M | −$408,000 | −7.37% |
| Q1 2023 | 2023-03-31 | $47.6M | $44.0M | +1231.50% |
| Q4 2022 | 2022-12-31 | $11.0M | $9.6M | +678.26% |
| Q3 2022 | 2022-09-30 | $7.0M | $5.8M | +482.46% |
| Q2 2022 | 2022-06-30 | $5.5M | $2.4M | +78.93% |
| Q1 2022 | 2022-03-31 | $3.6M | $3.1M | +723.73% |
| Q4 2021 | 2021-12-31 | $1.4M | −$85,000 | −5.66% |
| Q3 2021 | 2021-09-30 | $1.2M | $10,000 | +0.84% |
| Q2 2021 | 2021-06-30 | $3.1M | $2.6M | +516.53% |
| Q1 2021 | 2021-03-31 | $434,000 | −$327,000 | −42.97% |
| Q4 2020 | 2020-12-31 | $1.5M | $774,000 | +106.32% |
| Q3 2020 | 2020-09-30 | $1.2M | $956,000 | +403.38% |
| Q2 2020 | 2020-06-30 | $502,000 | $345,000 | +219.75% |
| Q1 2020 | 2020-03-31 | $761,000 | $761,000 | — |
| Q4 2019 | 2019-12-31 | $728,000 | −$751,000 | −50.78% |
| Q3 2019 | 2019-09-30 | $237,000 | −$40.6M | −99.42% |
| Q2 2019 | 2019-06-30 | $157,000 | −$8.9M | −98.26% |
| Q1 2019 | 2019-03-31 | $0 | −$8.2M | −100.00% |
| Q4 2018 | 2018-12-31 | $1.5M | −$2.8M | −65.36% |
| Q3 2018 | 2018-09-30 | $40.8M | $13.6M | +50.05% |
| Q2 2018 | 2018-06-30 | $9.0M | $5.5M | +156.69% |
| Q1 2018 | 2018-03-31 | $8.2M | $5.3M | +186.87% |
| Q4 2017 | 2017-12-31 | $4.3M | −$4.3M | −49.98% |
| Q3 2017 | 2017-09-30 | $27.2M | $24.8M | +1025.21% |
| Q2 2017 | 2017-06-30 | $3.5M | $3.2M | +973.48% |
| Q1 2017 | 2017-03-31 | $2.9M | −$61,000 | −2.09% |
| Q4 2016 | 2016-12-31 | $8.5M | $4.5M | +111.76% |
| Q3 2016 · Sep 30 | 2016-09-30 | $2.4M | −$2.5M | −51.17% |
| Q2 2016 · Jun 30 | 2016-06-30 | $328,000 | −$2.5M | −88.21% |
| Q3 2016 · Mar 31 | 2016-03-31 | $2.9M | $190,000 | +6.96% |
| Q2 2016 · Dec 31 | 2015-12-31 | $4.0M | — | — |
| Q1 2016 | 2015-09-30 | $4.9M | — | — |
| Q4 2015 | 2015-06-30 | $2.8M | — | — |
| Q3 2015 | 2015-03-31 | $2.7M | — | — |
Adaptimmune Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $1.1M to $178.0M, a compound annual growth rate of 175.49%. Adaptimmune Therapeutics's latest reported quarter, Q2 2025, generated $13.7M in revenue, a decrease of 89.33% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Adaptimmune Therapeutics source filings ↗